{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T03:04:38Z","timestamp":1763348678320,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"2022 Hubei Provincial Natural Science Foundation Youth Project","award":["2022CFB797","2022CFB797","2022CFB797"],"award-info":[{"award-number":["2022CFB797","2022CFB797","2022CFB797"]}]},{"DOI":"10.13039\/501100004241","name":"China Primary Health Care Foundation","doi-asserted-by":"publisher","award":["cphcf-2023-101","cphcf-2023-101","cphcf-2023-101"],"award-info":[{"award-number":["cphcf-2023-101","cphcf-2023-101","cphcf-2023-101"]}],"id":[{"id":"10.13039\/501100004241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Biochem Biophys"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s12013-024-01392-9","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T13:04:57Z","timestamp":1720789497000},"page":"2759-2766","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Blockade of PD-1 and TIM-3 Ameliorates CD8+ T Cell Exhaustion in a Mouse Model of Chronic Myeloid Leukemia"],"prefix":"10.1007","volume":"82","author":[{"given":"Ting","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"issue":"1","key":"1392_CR1","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1080\/10428194.2021.1975191","volume":"63","author":"JW Jacobs","year":"2022","unstructured":"Jacobs, J. W., et al. (2022). Chronic myeloid leukemia with pure erythroid leukemia blast crisis. Leuk Lymphoma, 63(1), 212\u2013216.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"1392_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s13238-015-0143-7","volume":"6","author":"H Zhou","year":"2015","unstructured":"Zhou, H., & Xu, R. (2015). Leukemia stem cells: the root of chronic myeloid leukemia. Protein Cell, 6(6), 403\u2013412.","journal-title":"Protein Cell"},{"issue":"1","key":"1392_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3390\/cells10010117","volume":"10","author":"VR Minciacchi","year":"2021","unstructured":"Minciacchi, V. R., Kumar, R., & Krause, D. S. (2021). Chronic myeloid leukemia: a model disease of the past, present and future. Cells, 10(1), 117.","journal-title":"Cells"},{"issue":"2","key":"1392_CR4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00277-021-04406-1","volume":"100","author":"M Breccia","year":"2021","unstructured":"Breccia, M., et al. (2021). Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA). Ann Hematol, 100(2), 481\u2013485.","journal-title":"Ann Hematol"},{"key":"1392_CR5","doi-asserted-by":"publisher","first-page":"643382","DOI":"10.3389\/fonc.2021.643382","volume":"11","author":"H Mu","year":"2021","unstructured":"Mu, H., et al. (2021). Combination therapies in chronic myeloid leukemia for potential treatment-free remission: focus on leukemia stem cells and immune modulation. Front Oncol, 11, 643382.","journal-title":"Front Oncol"},{"key":"1392_CR6","doi-asserted-by":"crossref","unstructured":"Baessler, A. & Vignali D. A. A. (2024). T Cell Exhaustion. Annu Rev Immunol, 42(1), 179\u2013206 .","DOI":"10.1146\/annurev-immunol-090222-110914"},{"issue":"6","key":"1392_CR7","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/s41590-022-01224-z","volume":"23","author":"JA Belk","year":"2022","unstructured":"Belk, J. A., Daniel, B., & Satpathy, A. T. (2022). Epigenetic regulation of T cell exhaustion. Nat Immunol, 23(6), 848\u2013860.","journal-title":"Nat Immunol"},{"key":"1392_CR8","doi-asserted-by":"publisher","first-page":"840610","DOI":"10.3389\/fimmu.2022.840610","volume":"13","author":"JA Wik","year":"2022","unstructured":"Wik, J. A., & Sk\u00e5lhegg, B. S. (2022). T cell metabolism in infection. Front Immunol, 13, 840610.","journal-title":"Front Immunol"},{"key":"1392_CR9","doi-asserted-by":"publisher","first-page":"1078118","DOI":"10.3389\/fimmu.2023.1078118","volume":"14","author":"D Yao","year":"2023","unstructured":"Yao, D., et al. (2023). Comprehensive analysis of the immune pattern of T cell subsets in chronic myeloid leukemia before and after TKI treatment. Front Immunol, 14, 1078118.","journal-title":"Front Immunol"},{"issue":"10","key":"1392_CR10","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1002\/eji.201040404","volume":"40","author":"S Mumprecht","year":"2010","unstructured":"Mumprecht, S., et al. (2010). Chronic myelogenous leukemia maintains specific CD8(+) T cells through IL-7 signaling. Eur J Immunol, 40(10), 2720\u20132730.","journal-title":"Eur J Immunol"},{"issue":"9","key":"1392_CR11","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1182\/blood-2013-08-523001","volume":"123","author":"P Bachireddy","year":"2014","unstructured":"Bachireddy, P., et al. (2014). Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood, 123(9), 1412\u20131421.","journal-title":"Blood"},{"issue":"1","key":"1392_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21099-2","volume":"12","author":"R Yang","year":"2021","unstructured":"Yang, R., et al. (2021). Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Commun, 12(1), 832.","journal-title":"Nat Commun"},{"issue":"7","key":"1392_CR13","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41375-018-0175-0","volume":"32","author":"O Br\u00fcck","year":"2018","unstructured":"Br\u00fcck, O., et al. (2018). Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML. Leukemia, 32(7), 1643\u20131656.","journal-title":"Leukemia"},{"key":"1392_CR14","doi-asserted-by":"publisher","first-page":"1323914","DOI":"10.3389\/fonc.2024.1323914","volume":"14","author":"P Pophali","year":"2024","unstructured":"Pophali, P., Varela, J. C., & Rosenblatt, J. (2024). Immune checkpoint blockade in hematological malignancies: current state and future potential. Front Oncol, 14, 1323914.","journal-title":"Front Oncol"},{"issue":"2","key":"1392_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1182\/blood-2015-01-622936","volume":"126","author":"F McClanahan","year":"2015","unstructured":"McClanahan, F., et al. (2015). PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. Blood, 126(2), 203\u2013211.","journal-title":"Blood"},{"issue":"8","key":"1392_CR16","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1182\/blood-2008-09-179697","volume":"114","author":"S Mumprecht","year":"2009","unstructured":"Mumprecht, S., et al. (2009). Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood, 114(8), 1528\u20131536.","journal-title":"Blood"},{"issue":"8","key":"1392_CR17","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1182\/blood-2011-06-361691","volume":"119","author":"H Yuan","year":"2012","unstructured":"Yuan, H., et al. (2012). Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood, 119(8), 1904\u20131914.","journal-title":"Blood"},{"issue":"10","key":"1392_CR18","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1084\/jem.20100643","volume":"207","author":"K Sakuishi","year":"2010","unstructured":"Sakuishi, K., et al. (2010). Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med, 207(10), 2187\u20132194.","journal-title":"J Exp Med"},{"key":"1392_CR19","doi-asserted-by":"publisher","first-page":"753677","DOI":"10.3389\/fonc.2021.753677","volume":"11","author":"M Rezaei","year":"2021","unstructured":"Rezaei, M., et al. (2021). TIM-3 in Leukemia; immune response and beyond. Front Oncol, 11, 753677.","journal-title":"Front Oncol"},{"issue":"8","key":"1392_CR20","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry, E. J., & Kurachi, M. (2015). Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol, 15(8), 486\u2013499.","journal-title":"Nat Rev Immunol"},{"key":"1392_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cellimm.2016.12.002","volume":"313","author":"M Barathan","year":"2017","unstructured":"Barathan, M., et al. (2017). CD8+ T cells of chronic HCV-infected patients express multiple negative immune checkpoints following stimulation with HCV peptides. Cell Immunol, 313, 1\u20139.","journal-title":"Cell Immunol"},{"issue":"11","key":"1392_CR22","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1182\/bloodadvances.2022008854","volume":"7","author":"YD Irani","year":"2023","unstructured":"Irani, Y. D., et al. (2023). Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia. Blood Adv, 7(11), 2364\u20132374.","journal-title":"Blood Adv"},{"issue":"2","key":"1392_CR23","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok, J. D., et al. (2013). Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med, 369(2), 122\u2013133.","journal-title":"N Engl J Med"},{"issue":"4","key":"1392_CR24","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/CJI.0000000000000122","volume":"39","author":"J Liu","year":"2016","unstructured":"Liu, J., et al. (2016). Targeting PD-1 and Tim-3 pathways to reverse CD8 T-cell exhaustion and enhance ex vivo T-cell responses to autologous dendritic\/tumor vaccines. J Immunother, 39(4), 171\u2013180.","journal-title":"J Immunother"},{"issue":"17","key":"1392_CR25","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","volume":"117","author":"Q Zhou","year":"2011","unstructured":"Zhou, Q., et al. (2011). Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood, 117(17), 4501\u20134510.","journal-title":"Blood"}],"container-title":["Cell Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-024-01392-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12013-024-01392-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-024-01392-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T14:32:13Z","timestamp":1727793133000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12013-024-01392-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1392"],"URL":"https:\/\/doi.org\/10.1007\/s12013-024-01392-9","relation":{},"ISSN":["1085-9195","1559-0283"],"issn-type":[{"type":"print","value":"1085-9195"},{"type":"electronic","value":"1559-0283"}],"subject":[],"published":{"date-parts":[[2024,7,12]]},"assertion":[{"value":"26 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"All animal experiments were in accordance with the relevant provisions of the Hubei Provincial Animal Management Committee\u2019s Experimental Animal Ethics Certificate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Conflict of Interest"}}]}}